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AbstrACt
Background: The management of end-stage kidney disease constitutes a heavy burden on communities worldwide 
due to the high cost of renal replacement therapy (RRT). Data on the cost of RRT are scanty in low-income 
countries. This study aimed to evaluate the global cost of haemodialysis in Cameroon, an emerging economy in 
Central Africa. This will provide data to help healthcare planners develop more cost-effective strategies for the care 
of these patients. 
Methods: A prospective cost analysis of chronic haemodialysis care in three public-sector facilities was conducted 
in Cameroon. Both incident and prevalent patients were enrolled and followed up for 6 months. Patient data and 
costs were collected from patient interviews, medical records, bills, hospital price-lists and the procurement 
departments of the hospitals. Direct medical costs included outpatient consultation fees, dialysis consumables, 
dialysis session fees, drugs, laboratory and radiological tests. Non-medical direct costs included the cost of transport, 
feeding, water and electricity. Indirect costs related to the monthly loss of productivity for patients and their 
caretakers. The annual costs were calculated as the median costs for 6 months multiplied by 2 and were expressed 
in the local currency, the Central African franc (XAF), and US dollars ($). 
results: A total of 154 patients (62.3% males), mean age of 46.8 ± 15.2 years, were included, with 6 130 dialysis 
sessions completed during the study period. The annual median cost of haemodialysis per patient was XAF 7 988 
800 ($ 13 581). Out-of-pocket payments amounted to XAF 2 420 300 ($ 4 114), accounting for 30% of the total 
cost. The median direct cost was XAF 7 458 200 ($ 12 679) and indirect cost XAF 530 600 ($ 902). Direct 
medical costs accounted for 88%, mainly due to dialysis consumables. In the initiation phase, additional costs of 
$ 754 were incurred. The cost of hospitalization, laboratory and radiology tests, feeding, consultation fees and some 
drugs varied significantly among facilities.
conclusions: Compared to the national gross domestic product per capita in Cameroon, the cost of care of patients 
on haemodialysis is high. Out-of-pocket payments are out of the reach of most patients and there is a need for 
implementing other cost-effective strategies to prevent and manage end-stage kidney disease in our setting.
Keywords: cost analysis, haemodialysis, peritoneal dialysis, Cameroon.
INtrODUCtION
The availability of renal replacement therapy (RRT) such 
as dialysis and transplantation for the treatment of end-
stage renal disease (ESRD) has been one of the great 
successes of medicine in past decades. It has been avail-
able in high-income countries for more than 50 years, 
with rapid growth in the number of people treated [1,2]. 
The use of dialysis varies among regions, due to differ-
ences in population demographics, prevalence of ESRD, 
and especially access to and provision of RRT [3,4]. The 
management of renal failure is disproportionately costly 
in comparison with other medical conditions and consti-
tutes a heavy burden on communities worldwide [5–7]. 
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RRT consumes many resources, the equipment and 
consumables are expensive and skilled personnel are 
required [8]. In contrast to high- and middle-income 
countries, data on the cost of RRT is sparse in low-income 
nations, especially in sub-Saharan Africa (SSA) [6,7,9]. In 
2010, the annual cost for ESRD-related medical expenses 
in the USA was estimated at $*28 billion [3] In the UK, 
the cost of treatment for ESRD was 1–2% of the budget of 
the National Health Service, for patients who constituted 
only 0.05% of the population [10]. 
Globally, the number of patients receiving RRT in 2010 was 
estimated at 2.618 million, with only 7.2% living in lower-
middle income and low-income countries. Further model-
ling suggests that this number will more than double to 
5.439 million by 2030, mostly in developing countries. 
African patients with ESRD have the lowest access to RRT, 
with only 9–16% being treated; in central and eastern Africa 
the treatment rate is estimated to be as low as 1–3% [2].
In SSA, in-centre haemodialysis (HD) is the most common 
modality of RRT with its provision being very challenging. 
Treatment for all is beyond the reach of most countries 
due to the lack of funds or health insurance to cover the 
high costs for the ever-increasing number affected. Despite 
this high disease burden, renal registries are almost non-
existent and there is a lack of published data on the costs 
of dialysis in African countries [7,11,12]. 
Cameroon is a low-income country, with a population of 
22.5 million. The human development indices are poor, 
with a low gross domestic product of $ 34 billion in 2015 
and only 5.1% of the country’s budget being spent on 
health care [13]. The prevalence of chronic kidney disease 
(CKD) in Cameroon is estimated at 10–13.2% [14,15]. In-
centre haemodialysis started in the early 1980s and in the 
last decade much attention has been focused on the treat-
ment of ESRD with the establishment of public haemodialysis 
centres nationwide [16]. About 1 200 patients were on 
treatment in 9 public-sector treatment centres at the end 
of 2016. Since 2002, dialysis sessions have been subsidized 
by the government in public-sector centres. Patients pay a 
fee of XAF 5000 ($ 8.5) per dialysis session. This does not 
include related costs for vascular access, laboratory tests, 
medication, feeding, transportation, hospitalization and vac-
cination. All these additional costs are borne by patients 
and their families. This study aimed to evaluate the global 
cost of ESRD treated by HD in a resource-limited country, 
to help healthcare planners to develop strategies to mini-
mize the cost of care of these patients.
MEtHODs
A prospective cost-analysis of HD care was conducted in 
3 facilities in Cameroon (two tertiary, one regional). All 
centres are equipped with Fresenius 4008S dialysis ma-
chines, use consumables produced by the manufacturers 
and do not practise dialyzer reuse. In these centres, as in 
other centres in Cameroon, patients undergo two dialysis 
sessions of 4 hours per week.
We included consenting incident and prevalent patients 
on HD for ESRD and followed them up for 6 months 
from November 2012 to April 2013. Outcomes of interest 
were expenditure by patient or their families as well as by 
the hospital in relation to HD care. Staff salaries and other 
utilities, furniture and cost of maintenance of the building 
were excluded from the analysis. Data and costs were 
obtained from patient interviews, medical records, bills, 
hospital price-lists and procurement departments of the 
hospitals. Direct costs analysed included direct medical 
costs (dialysis session fees, cost of consumables, drugs, 
outpatient consultation fees, laboratory and radiological 
tests) and direct non-medical costs (transport, feeding, 
water and electricity). One indirect cost considered was 
the monthly loss of productivity for patients and their 
caretakers estimated from the time spent for the treat-
ment. Out-of-pocket payments (borne by patients and 
families) included dialysis session fees, vascular access, all 
drugs, laboratory and radiology tests, vaccinations, meals 
and transportation. All other costs were borne by the 
government/hospital.
The cost of incident patients was used to calculate the cost 
at the initiation phase. The cost of electricity and water was 
calculated with the assistance of an engineer at each 
hospital. Electricity consumption was calculated by taking 
into account all electrical appliances at each unit, con-
sumption by each appliance, and the duration of its usage 
per month. Water consumption was calculated by multi-
plying hours of dialysis by the hourly water usage per 
dialysis machine, and the number of machines at each 
dialysis unit. 
Data analysis used SAS/STAT® v 9.1 for Windows (SAS 
Institute Inc., Cary, NC, USA). We reported results using 
counts and percentages, means and standard deviations 
(SD) or median (min–max). Comparisons across study 
centres were made using the chi-squared test and analysis 
of variance (ANOVA). Costs were expressed as the 
median of the expenditure recorded over 6 months per 
patient in the local currency) and converted to US dollars, 
based on the exchange rate at the end of the study (1 XAF 
= $ 0.0017). We estimated the annual cost by multiplying 
cost of haemodialysis in cameroon
*$ represents US dollars; the currency of Cameroon is the Central African franc (XAF).]
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the median cost by 2. A p-value < 0.05 was considered 
statistically significant.
The study received administrative authorization from the 
Douala General Hospital and ethical approval was obtained 
from the ethical board of Douala University.
 
rEsULts 
Of the 154 participants included, 106 (68.8%) were pre-
valent and 48 (31.2%) were incident patients. The mean 
age was 46.8 ± 15.2 years and 96 (62.3%) were males, with 
no difference between centres. The majority of our patients 
were in a low socio-economic class with more than 25% 
without income. Only 9% had medical insurance. The total 
number of dialysis sessions included was 6130 (mean 39.8 
sessions per patient). See Table 1.
The median cost of haemodialysis per patient for 6 
months was XAF 3 994 400 ($ 6 790), an annual cost of 
XAF 7 988 800 ($ 13 581). Out-of-pocket payments per 
patient was XAF 2 420 300 ($ 4 114), accounting for 30.3% 
of the total cost. Direct costs totalled XAF 7 458 200 
($ 12 679) and indirect costs XAF 530 600 ($ 902). Direct 
medical costs accounted for 87.7% ($ 11 904) of the total 
costs, mainly due to the cost of dialysis consumables 
(59.8%, $ 8120). Direct non-medical costs accounted for 
5.7% ($ 775) and indirect costs for 6.6% ($ 902) of the 
total cost (Table 2).
In the initiation phase, additional costs of $ 775 were 
incurred, mainly due to the cost of vascular access, drugs 
and hospitalization (Table 3).
The itemized costs at each hospital are shown in Table 4. 
The costs of hospitalization (p <0.013), laboratory and 
radiology tests (p <0.001), some drugs (p <0.005), con-
sultation fees and feeding (p <0.001) varied significantly 
among facilities.
cost of haemodialysis in cameroon
table 1. baseline characteristics of the study population at the different dialysis centres.
DgH YgH BrH p total
N (%) 70 (45.5) 41 (26.6) 43 (27.9) 154 (100.0)
Men (%) 42 (60.0) 29 (70.7) 25 (58.1) 0.42 96 (62.3)
Mean age, years (SD) 46.6 (15.16) 46.04 (14.80) 47.76 (15.76) 0.88 46.77 (15.15)
level of formal education, n (%)
  None 1 (1.4) 0 (0.0) 2 (4.7) 3 (1.9)
  Primary 14 (20.0) 4 (9.8) 11 (25.6) 29 (18.8)
  Secondary 33 (47.1) 19 (46.3) 16 (37.2) 68 (44.2)
  University 22 (31.4) 18 (43.9) 14 (32.6) 0.24 54 (35.1)
Place of residence, n (%)
  Same town as dialysis centre 67 (95.7) 37 (90.2) 26 (60.5) 130 (84.4)
  Out of town 3 (4.3) 4 (9.8) 17 (39.5) <0.0001 24 (15.6)
Monthly income (XFA), n (%)
  No income 21 (30.0) 9 (22.0) 10 (23.3) 40 (26.0)
  <22 500 1 (1.4) 1 (2.4) 3 (7.0) 5 (3.2)
  22 500–50 000 13 (18.6) 7 (17.1) 6 (14.0) 26 (16.9)
  50 000–100 000 13 (18.6) 4 (9.8) 7 (16.3) 24 (15.6)
  100 000–200 000 13 (18.6) 8 (19.5) 11 (25.6) 32 (20.8)
  200 000–300 000 1 (1.4) 6 (14.6) 4 (9.3) 11 (7.1)
  >300 000 8 (11.4) 6 (14.6) 2 (4.7) 0.21 16 (10.4)
Insurance, n (%) 11 (15.7) 2 (4.9) 1 (2.3) 0.024 14 (9.1)
Number of dialysis machines 16 12 7 35
Number of dialysis sessions 2 855 1 602 1 673 6 130
DGH, Douala General Hospital; YGH, Yaounde General Hospital; BRH, Buea Regional Hospital.
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DIsCUssION
The reported cost of dialysis varies considerably among 
regions and countries [7]. Our annual cost was approxi-
mately $ 13 581, with out-of-pocket payments accounting 
for 30%. This is close to that reported in Iran ($ 11 549) 
[17] but is lower than in most developed countries and 
some low-income nations. The annual cost of haemo-
dialysis has been estimated at $ 87 500 in the USA [18], 
between $ 22 000–55 000 in Nigeria [19,20], $ 46 332 in 
Saudi Arabia [21], $ 27 440 in Tanzania [22] and $ 28 570 
in Brazil [23]. One of the reasons for our lower cost is that 
we did not include the staff and building costs as has been 
done in other studies.
Lower costs have been reported in low/middle-income 
countries such as Indonesia ($4900–6500) [24], South 
Africa ($7000) [16], Sri Lanka ($5869–8804) [25], Sudan 
($6847) [26] and India ($3000) [27]. These differences 
may be explained by many factors including the annual per 
capita income of countries, the methods used in estimating 
costs, different management protocols, and differences in 
local import duties, drugs, laboratory tests and the costs of 
consumables.
The main contributors to cost in our study were those 
related to the dialysis procedure and, in particular, the 
haemodialysis consumables. Similar results were reported 
in Sri Lanka [28] and in Brazil [23] whereas in Europe the 
haemodialysis procedure accounts for only 29–53% of the 
cost [29–31]. Like most SSA countries, we import all dialysis 
supplies from Europe, so the cost of transportation, 
cost of haemodialysis in cameroon
table 2. Global annual costs of haemodialysis per patient.
XAF $ %
Direct costs 7 458 199 12 679 93.4
Medical  7 002 478 11 905 87.7
  Dialysis session fees* 480 000 (120 000–640 000) 816 6.0
  Dialysis consumables* 4 776 623 8 120 59.8
   Vascular access* 217500 (60 000–575800) 370 2.7
  Blood transfusions* 216 950 (30 000–697 000) 369 2.7
  Drugs for hypertension* 164 260 (13 560–698 614) 279 2.1
  Heparin* 74 100 (7 450–526 296) 80 0.6
  Other drugs* 105 215 (200–621 680) 179 1.3
  Erythropoietin* 560 000 (20 000–4 272 000) 952 7.0
  Iron* 41 600 (4 900–480 000) 71 0.5
  Laboratory and radiology tests* 123 930 (2 000–1 020 800) 211 1.6
  Hospitalization* 247 300 (20 000–6 801 098) 420 3.1
  Consultation fees* 14 000 (1 200–84 000) 24 0.2
   Vaccinations* 8000 (7 000–21 000) 14 0.1
Non-medical 455 721 774 5.7
  Transportation* 122 400 (3 000–1 704 000) 208 1.5
  Meals* 72 000 (4 800–352 800) 122 0.9
  Water* 26 062 44 0.3
  Electricity 235 259 400 2.9
Indirect costs 530 562 902 6.6
total out-of-pocket costs 2 420 255 4 114 30.3
total state/hospital costs 5 037 944 8 565 63.1
total costs 7 988 761 13 581 100.0
* Median (min–max).
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currency exchange and import duties all add to the cost of 
these items. 
The cost of consultation fees, feeding, drugs, hospitalisation, 
laboratory and radiology tests varied among our facilities. 
These were higher in Douala, the economic capital of 
Cameroon, compared to Buea, a rural town. This probably 
reflects the stratification of healthcare costs according to 
the economic standards of towns within the country. Direct 
medical costs accounted for almost 90% of our costs and 
were dominated by the cost of dialysis consumables.
Dialysis is relatively more expensive for poorer than for 
richer developing countries and may not be cost-effective 
for low-income countries such as Cameroon [7,11]. Com-
pared to the national income, the costs of haemodialysis 
are prohibitive, and beyond the financial capacity of most 
governments. In Cameroon only 5.1% ($ 1.3 billion) of the 
budget is allocated to health care. With other burning 
health issues such as high maternal and infant mortality, 
HIV/AIDS and undernutrition, haemodialysis becomes a 
serious economic burden on the healthcare sector [13]. 
Despite the government subsidies, the out-of-pocket 
expenditure borne by patients and their families is almost 
one-third of the total cost. This is extremely high, especially 
in the initiation phase when there are the additional costs 
of vascular access, drugs and hospitalisation. This is out of 
the reach of most of our patients, who belong to the lower 
socio-economic class and often have no income. In our 
setting, health insurance is almost non-existent. Other 
studies have also shown that in countries in SSA, even 
cost of haemodialysis in cameroon
table 3. Cost of haemodialysis in the initiation and maintenance phases of dialysis.
Initiation Maintenance p
XAF $ XAF $
Direct costs 7 678 553 13 054 7 232 433 12 273
Medical  7 220 833 12 277 6 762 313 11 495
  Dialysis session fees* 437 500 (120 000–530 000) 744 490 000 (270 000–640 000) 833 <0.001
  Dialysis consumables* 4 776 623 8 120 4 776 623 8 120 >0.999
   Vascular access* 217 500 (60 000–575800) 370 – –
  Blood transfusions* 268 000 (73 000–671 250) 456 201 250 (30 000–697 000) 342 0.005
  Drugs for hypertension* 185 180 (68 120–698 614) 315 137 600 (13 560–593 400) 234 0.010
  Heparin* 89 400 (8 100–526 296) 152 66 300 (7450–263 580) 113 0.028
  Other drugs* 133 670 (24 400–597 240) 227 92 040 (200–621 680) 156 0.001
  Erythropoietin* 460 000 (40000–4 272 000) 782 580 000(20 000–1 800 000) 986 0.387
  Iron* 56 600 (13 800–480 000) 96 41 000 (4900–219 600) 70 0.181
  Laboratory and radiology tests* 195 600 (4 000–1 624 144) 333 110 200 (2000–650 600) 187 0.001
  Hospitalization* 375 960 (30 400–6 801 098) 639 247 300 (23 000–3 364 566) 420 0.112
  Consultation fee* 16 800 (1 800–84 000) 29 12 000 (1 200–42 000) 20 <0.001
   Vaccinations* 8 000 (8000–8000) 14 8 000 (7000–21 000) 14 >0.999
Non-medical 457 720 777 470 120 778
  Transportation* 122 000 (3 000–834 000) 207 122 400 (15 200–1 704 000) 208 0.612
  Meals* 74 400 (4 800–212 200) 126 86 400 (5 000–352 800) 126 0.122
  Water* 26 062 44 26 062 44 >0.999
  Electricity 235 258 400 235 258 400 >0.999
Indirect costs 530 118 901 532 668 906
total out-of-pocket costs 2 640 610 4 489 2 194 490 3 709
total state/hospital costs 5 037 943 8 565 5 037 943 8 565
total costs 8 208 671 13 955 7 765 101 13 180
* Median (min–max).
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when the state subsidizes dialysis, the cost covered by 
patients is high and the majority cannot afford it. Morbidity 
and mortality are consequently high [32–41]. 
In SSA, poverty is rampant and over 40% of the population 
is estimated to live on less than one dollar per day [42]. 
Given the constant increase in the number of patients 
requiring dialysis in Cameroon, and considering that 
haemodialysis is the only modality available, it is impera- 
tive to identify cost-effective strategies to meet the 
demand for renal services. There is a need for policy-
makers in low-income countries to look for ways to reduce 
the cost of dialysis. One major step could be that govern-
ments build infrastructure to produce dialysis supplies and 
generic medications locally, and remove the import duty 
charged on dialysis consumables. Renal transplantation, 
which is a more cost-effective treatment for ESRD, remains 
underutilized in SSA, and Cameroon in particular, due to 
lack of qualified health personnel and appropriate infra-
structure [43,44]. The most important factor is to reduce 
the number of patients developing ESRD. Identification and 
optimal treatment of CKD in high-risk populations, espe-
cially in resource-limited settings, remains the only cost-
effective and sustainable means of curbing the cost of 
managing ESRD. However, this approach is still in its infancy 
in most SSA countries and is not subsidized by the state in 
Cameroon [45–47]. 
Some limitations of this study include the fact that we did 
not incorporate the costs of staff overheads, infrastructure 
and utilities such as sanitation and laundry. Also, we based 
our calculations on actual expenditure, which may lead to 
an underestimation since certain items are self-funded and 
patients pay for what they can afford, not for what they 
need. Despite these limitations, this study provides the 
first estimates of the operational costs of haemodialysis 
table 4. Itemized annual costs of haemodialysis per patient in the 3 centres (XAF).
DgH
(n = 70)
YgH
(n = 41)
BrH 
(n =43)
p
Dialysis session fee* 480 000 (160 000–640 000) 495 000 (120 000–560 000) 480 000 (280 000–530 000) 0.270
Dialysis consumables 4 894 285 4 688 780 4 668 837
Water 26 770 25 675 25 497
electricity 285 454 396 293 256 186
Medications  
  EPO* 580 000 (20 000–4 272 000) 556 000 (96 000–856 000) 520 500 (144 000–1 800 000) 0.444
  Iron* 38 900 (4 900–480 000) 64 000 (8 000–168 000) 20 600 (13 800–84 600) 0.160
  Blood transfusion* 205 500 (36 500–671 250) 277 200 (55 800–697 000) 217 500 (30 000–690 000) 0.229
  Hypertension drugs* 167 865 (42 000–698 614) 202 380 (13 560–593 400) 129 945 (13 800–356 000) 0.346
  Heparin* 82 600 (32 400–526 296) 37 800 (8 100–196 600) 26 400 (7 450–134 100) <0.001
  Other medications* 120 800 (26 000–597 240) 82 900 (8 100–238 680) 24 000 (100–310 840) <0.001
laboratory and radiology* 152 800 (27 000–1 020 800) 162 450 (19 400–800 400) 27 000 (2 000–434 400) <0.001
consultation fees* 14 000 (10 200–84 000) 7 500 (6 000–84 000) 1 800 (1 200–14 400) <0.001
Feeding* 80 800 (4 800–352 800) 104 000 (5000–255 000) 61 600 (12 800–336 000) <0.001
transport* 114 000 (3 840–714 000) 119 400 (3 000–1 642 200) 174 500 (23 200–1 704 000) 0.163
Vascular access* 172 000 (60 000–575 800) 142 500 (42 500–385 000) 107 500 (60 000–570 000) 0.850
Hospitalization*  1 399 240 (30 400–6 801 098) 382 950 (40 000–1 698 070) 179 400 (23 000–815 000) 0.013
Vaccination* 42 000 (42 000–42 000) 16 000 (16 000–16000) 7 000 (7 000–7 000) 0.223
Patient’s time* 246 528 (0–1 166 754) 289 542 (0–605 382) 266 058 (0–874 682) 0.175
total out-of-pocket costs 3 650 505 2 650 080 1 730 411
total state/hospital costs 5 206 509 5 110 748 4 719 831
total costs 9 103 542 8 050 370 6 716 300
* Median (min–max).
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in Cameroon, where this therapy has been available for 
more than two decades. The results will help healthcare 
planners to develop strategies to improve the care of 
these patients.
CONCLUsIONs
This multi-centre study demonstrated that the global cost 
of care of patients on haemodialysis in Cameroon is 
extremely high compared with the national gross domestic 
product per capita and that it is mainly due to the cost of 
dialysis consumables. Most patients are at a low socio-
economic level and, despite the state subsidy, out-of-
pocket expenditure is extremely high and unaffordable by 
patients and their relatives in the long term. Haemodialysis 
is an economic burden on the country, and therefore 
strategies such as removing import duties on dialysis 
consumables and establishing kidney transplantation should 
be implemented. CKD screening and prevention pro-
grammes to reduce the number of persons in need of RRT 
are necessary and this remains the only cost-effective and 
sustainable approach, especially in developing countries.
Acknowledgment
We sincerely thank all the patients who participated in this 
study.
Conflict of interest
None to declare.
rEFErENCEs
1.   Lysaght MJ. Maintenance dialysis population dynamics: current  
trends and long-term implications. J Am Soc Nephrol. 2002;  
13(Suppl 1):S37–40. 
2.   Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. 
Worldwide access to treatment for end-stage kidney disease:  
a systematic review. Lancet. 2015; 385(9981):1975–1982. 
3.   Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, 
et al. United States Renal Data System 2011 Annual Data Report.  
Am J Kidney Dis. 2012; 59(Suppl 1):A7, e1–420. 
4.   Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. 
Chronic kidney disease: global dimension and perspectives.  
Lancet. 2013; 382(9888):260–72. 
5.   Benain J-P, Faller B, Briat C, Jacquelinet C, Brami M, Aoustin M, et al. 
Coût de la prise en charge de la dialyse en France. Néphrologie 
Thérapeutique. 2007; 3(3):96–106. 
6.    De Vecchi AF, Dratwa M, Wiedemann ME. Healthcare systems and 
end-stage renal disease (ESRD) therapies-an international review: 
costs and reimbursement/funding of ESRD therapies. Nephrol Dial 
Transplant.1999; 14(Suppl 6):31–41. 
  7.    Mushi L, Marschall P, Fleßa S. The cost of dialysis in low and middle-
income countries: a systematic review. BMC Health.  
2015; 15(1). 
  8.    Peeters P, Rublee D, Just PM, Joseph A. Analysis and interpretation 
of cost data in dialysis: review of Western European literature. 
Health Policy Amst Neth. 2000; 54(3):209–27. 
  9.    Karopadi AN, Mason G, Rettore E, Ronco C. Cost of peritoneal 
dialysis and haemodialysis across the world. Nephrol Dial 
Transplant. 2013; 28(10):2553–69. 
10.    UK Department of Health. The National Service Framework for 
Renal Services Part 1: Dialysis and Transplantation. 2004. https://
www.kidney.org.uk/documentlibrary/pt1-toolkit4comm.pdf.
11.   Alasia DD, Emem-Chioma P, Wokoma FS. A single-centre 7-year 
experience with end-stage renal disease care in Nigeria-a surrogate 
for the poor state of ESRD care in Nigeria and other sub-Saharan 
african countries: advocacy for a global fund for ESRD care  
program in sub-Saharan african countries. Int J Nephrol. 2012; 
Article ID 639653. 
12.   Bamgboye EL. Haemodialysis: management problems in developing 
countries, with Nigeria as a surrogate. Kidney Int Suppl.  
2003; (83):S93–95.
13.   Cameroon GDP and economic data. Global Finance Magazine. 
https://www.gfmag.com/global-data/country-data/cameroon-gdp-
country-report. Accessed 28 July 2016.
14.    Kaze FF, Halle MP, Mopa HT, Ashuntantang G, Fouda H, Ngogang J, 
et al. Prevalence and risk factors of chronic kidney disease in urban 
adult Cameroonians according to three common estimators of  
the glomerular filtration rate: a cross-sectional study. BMC Nephrol. 
2015; 16(1). 
15.    Kaze FF, Meto DT, Halle MP, Ngogang J, Kengne AP. Prevalence 
and determinants of chronic kidney disease in rural and urban 
Cameroonians: a cross-sectional study. BMC Nephrol. 2015; 16(1). 
16.    Kaze FF, Kengne AP, Choukem SP, Dzudie A, Halle M, Dehayem M, 
et al. Dialysis in Cameroon. Am J Kidney Dis. 2008; 51(6):1072–1074; 
17.    Arefzadeh A, Lessanpezeshki M, Seifi S. The cost of haemodialysis in 
Iran. Saudi J Kidney Dis Transplant. 2009; 20(2):307–311. 
18.    Collins AJ, Foley RN, Gilbertson DT, Chen S-C. United States Renal 
Data System public health surveillance of chronic kidney disease 
and end-stage renal disease. Kidney Int Suppl. 2015; 5(1):2–7. 
19.    Abu-Aisha H, Elamin S. Peritoneal dialysis in Africa. Perit Dial Int. 
2010; 30(1):23–28. 
20.    Okafor C, Kankam C. Future options for the management of 
chronic kidney disease in Nigeria. Gend Med. 2012; 9(1):S86–93. 
21.    Al Saran K, Sabry A. The cost of haemodialysis in a large 
haemodialysis centre. Saudi J Kidney Dis Transplant. 2012; 
23(1):78–82. 
22.    Mushi L, Krohn M, Flessa S. Cost of dialysis in Tanzania: evidence 
from the provider’s perspective. Health Econ Rev. 2015; 5:28. 
23.    de Abreu MM, Walker DR, Sesso RC, Ferraz MB. A cost evaluation 
of peritoneal dialysis and haemodialysis in the treatment of 
end-stage renal disease in São Paulo, Brazil. Perit Dial Int.  
2013; 33(3):304–315.
24.    Prodjosudjadi W. Incidence, prevalence, treatment and cost of 
end-stage renal disease in Indonesia. Ethn Dis. 2006;  
16(Suppl 2): 14 – 16. 
237
cost of haemodialysis in cameroon
25.    Li PK, Chow KM. The cost barrier to peritoneal dialysis in the 
developing world-an Asian perspective. Perit Dial Int. 2001; 
21(Suppl 3):7–13. 
26.    Elsharif ME, Elsharif EG, Gadour WH. Costs of haemodialysis  
and kidney transplantation in Sudan: a single centre experience.  
Iran J Kidney Dis. 2010; 4(4):282–284. 
27.    Khanna U. The economics of dialysis in India. Indian J Nephrol. 
2009; 19(1):1. 
28.    Ranasinghe P, Perera YS, Makarim MFM, Wijesinghe A, 
Wanigasuriya K. The costs in provision of haemodialysis in a 
developing country: a multi-centered study. BMC Nephrol.  
2011; 12:42. 
29.    Eriksson JK, Neovius M, Jacobson SH, Elinder C-G, Hylander B. 
Healthcare costs in chronic kidney disease and renal replacement 
therapy: a population-based cohort study in Sweden. BMJ Open. 
2016; 6(10):e012062. 
30.    Lorenzo V, Perestelo L, Barroso M, Torres A, Nazco J. Economic 
evaluation of haemodialysis. Analysis of cost components based  
on patient-specific data. Nefrologia. 2010; 30(4):403–412. 
31.    Icks A, Haastert B, Gandjour A, Chernyak N, Rathmann W, Giani G, 
et al. Costs of dialysis-a regional population-based analysis.  
Nephrol Dial Transplant. 2010; 25(5):1647–1652. 
32.    Arogundade FA, Sanusi AA, Hassan MO, Akinsola A. The pattern, 
clinical characteristics and outcome of ESRD in Ile-Ife, Nigeria:  
is there a change in trend? Afr Health Sci. 2011; 11(4):594–601. 
33.    Sumaili EK, Cohen EP, Zinga CV, Krzesinski J-M, Pakasa NM, Nseka 
NM. High prevalence of undiagnosed chronic kidney disease among 
at-risk population in Kinshasa, the Democratic Republic of Congo. 
BMC Nephrol. 2009; 10:18. 
34.    Naicker S. End-stage renal disease in sub-Saharan and South Africa. 
Kidney Int. 2003; 63(Suppl 83):S119–122. 
35.    Bamgboye EL. Hemodialysis: management problems in developing 
countries, with Nigeria as a surrogate. Kidney Int. 2003; 63:S93–95. 
36.    Ashuntantang G, Osafo C, Olowu WA, Arogundade F, Niang A, 
Porter J, et al. Outcomes in adults and children with end-stage 
kidney disease requiring dialysis in sub-Saharan Africa: a systematic 
review. Lancet Glob Health. 2017; 5(4):e408–417. 
37.    Niang A, Cisse MM, Mahmoud SMOM, Lemrabott ATO, Ka EHF, 
Diouf B. Pilot experience in Senegal with peritoneal dialysis for 
end-stage renal disease. Perit Dial Int. 2014; 34(5):539–543. 
38.    Dreyer G, Dobbie H, Banks R, et al. Supporting Malawi’s dialysis 
services with the international community. Br J Renal Med.  
2012; 17:24–26. 
39.    Kaze FF, Ashuntantang G, Kengne AP, Hassan A, Halle MP,  
Muna W. Acute haemodialysis complications in end-stage renal 
disease patients: The burden and implications for the under-
resourced Sub-Saharan African health systems. Hemodial Int. 2016; 
16(4):526–531. 
40.    Bah AO, Nankeu N, Balde MC, Kaba ML, Bah BK-H, Rostaing L. 
Quality of life of patients with end-stage renal disease in Guinea. 
Saudi J Kidney Dis Transplant. 2014; 25(6):1346–1351. 
41.    Okafor UH, Ekwem I, Wokoma FS. Challenges of kidney care in  
a resource poor nation: A study of private kidney care centre in 
Nigeria. Niger Med J. 2012; 53(1):47–50. 
42.    Human Development Report 2003. United Nations. http://hdr.
undp.org/en/content/human-development-report-2003.
43.    Tshamba HM, Van Caillie D, Nawej FN, Kapend FM, Kaj FM,  
Yav GD, et al. Risk of death and the economic accessibility at the 
dialysis therapy for the renal insufficient patients in Lubumbashi city, 
Democratic Republic of Congo. Pan Afr Med J. 2014; 19:61. 
44.    Nayak Karopadi A, Mason G, Rettore E, Ronco C. The role of 
economies of scale in the cost of dialysis across the world:  
a macroeconomic perspective. Nephrol Dial Transplant.  
2014; 29(4):885–892. 
45.    Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, 
et al. Comparison of mortality in all patients on dialysis, patients on 
dialysis awaiting transplantation, and recipients of a first cadaveric 
transplant. N Engl J Med. 1999; 341(23):1725–1730. 
46.    Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, et al. 
A study of the quality of life and cost-utility of renal transplantation. 
Kidney Int. 1996; 50(1):235–242. 
47.    Klarenbach S, Manns B. Economic evaluation of dialysis therapies. 
Semin Nephrol. 2009; 29(5):524–532. 
